Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.41 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805213 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL9221661 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL911135 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL187269 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL3332706 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL21581247 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL493840 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL1149381 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL14688826 | 1.00 | THRB (0.47) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL10240 | 0.97 | THRB (0.41) | THRBTSHRMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | claimed |
| EP-2565973-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION CONTAINING CYCLIC SULFONE COMPOUND, AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | MITSUI CHEMICALS INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9303011-B2 | Nonaqueous electrolyte solution containing cyclic sulfone compound, and lithium secondary battery | MITSUI CHEMICALS, INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| EP-2565973-A1 | NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING CYCLIC SULFONE COMPOUND, AND LITHIUM SECONDARY BATTERY | Mitsui Chemicals, Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130040209-A1 | NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING CYCLIC SULFONE COMPOUND, AND LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS, INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | THRB 52/4885TSHR 79/4885MEN1 4827/4885 |
| US-20130040209-A1 | NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING CYCLIC SULFONE COMPOUND, AND LITHIUM SECONDARY BATTERY | TST, SULT1E1, STS | THRB 1436/4885TSHR 857/4885MEN1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.